Ultrasound-targeted transfection of tissue-type plasminogen activator gene carried by albumin nanoparticles to dog myocardium to prevent thrombosis after heart mechanical valve replacement

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 2911-2919

  Ji, Jun ^a   Ji, Shang Yi ^a   Yang, Jian An ^a   He, Xia ^a   Yang, Xiao Han ^a   Ling, Wen Ping ^a   Chen, Xiao Ling ^a  

^a Shenzhen Sun Yat sen Cardiovascular Hospital   (China)

Author keywords

Albumin nanoparticles; Ultrasonic microbubbles; Valve replacement

Indexed keywords

ALBUMIN NANOPARTICLE; D DIMER; DEOXYRIBONUCLEASE I; NANOPARTICLE; PLASMID DNA; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL DOG; FEMALE; GENE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE IDENTIFICATION; GENE VECTOR; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTERNATIONAL NORMALIZED RATIO; MALE; MICROBUBBLE; NANOENCAPSULATION; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; POWDER; PROTHROMBIN TIME; RISK REDUCTION; STRUCTURE ANALYSIS; THROMBOSIS; TISSUE TYPE PLASMINOGEN ACTIVATOR GENE; TRICUSPID VALVE REPLACEMENT; ULTRASOUND THERAPY; ZETA POTENTIAL;

ANIMALS; CATTLE; CHO CELLS; CORONARY THROMBOSIS; CRICETINAE; CRICETULUS; DOGS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROBUBBLES; MYOCARDIUM; NANOPARTICLES; PLASMIDS; POSTOPERATIVE COMPLICATIONS; PROTHROMBIN TIME; SERUM ALBUMIN, BOVINE; TISSUE PLASMINOGEN ACTIVATOR; TRANSFECTION; ULTRASONOGRAPHY;

BOVINAE; CANIS FAMILIARIS;

EID: 84870341869     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S32363     Document Type: Article

References (40)

1. Haibo Z, Jinzhong L, Yan L, Xu M. Low-intensity international normalized ratio (INR) oral anticoagulant therapy in Chinese patients with mechanical heart valve prostheses. Cell Biochem Biophys. 2012;62(1):147-151.
2. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol. 2000;36(4):1152-1158.
3. Florath I, Albert A, Rosendahl U, Alexander T, Ennker IC, Ennker J. Mid term outcome and quality of life after aortic valve replacement in elderly people: mechanical versus stentless biological valves. Heart. 2005;91(8):1023-1029.
4. Rhie S, Choi JY, Jang IS, Kim JW, Lee CW, Park HO. Relationship between the occurrence of thromboembolism and INR measurement interval in low intensity anticoagulation after aortic mechanical valve replacement. Korean J Thorac Cardiovasc Surg. Jun 2011;44(3):220-224.
5. Kaeberich A, Reindl I, Raaz U, etal. Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Thromb Thrombolysis. 2011;32(4):417-425.
6. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e89S-e119S.
7. Pamukcu B, Huber K, Lip GY. Antiplatelet therapy in atherothrombotic cardiovascular diseases for primary and secondary prevention: a focus on old and new antiplatelet agents. Curr Pharm Des. 2012;18(6):850-860.
8. Lansberg MG, O'Donnell MJ, Khatri P, etal. Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(Suppl 2):e601S-e636S.
9. Paez Espinosa EV, Murad JP, Khasawneh FT. Aspirin: pharmacology and clinical applications. Thrombosis. 2012;2012:173124.
10. Wilson AM, Brittenden J, Bachoo P, Ford I, Nixon GF. Randomized controlled trial of aspirin and clopidogrel versus aspirin and placebo on markers of smooth muscle proliferation before and after peripheral angioplasty. J Vasc Surg. 2009;50(4):861-869.
11. Wang MY, Gao CQ, Wang Y, Li BJ, Jiang SL, Ren CL. Analysis on the risk factors of intracardial thrombus after prosthetic valve replacement: a 1-year follow-up study. Zhonghua Wai Ke Za Zhi. 2010;48(7):522-525.
12. Majidzadeh AK, Khalaj V, Fatemeh D, etal. Cloning and expression of functional full-length human tissue plasminogen activator in Pichia pastoris. Appl Biochem Biotechnol. Nov 2010;162(7):2037-2048.
13. Ludwig M, Wohn KD, Schleuning WD, Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet. 1992;88(4):388-392.
14. Kim PY, Tieu LD, Stafford AR, Fredenburgh JC, Weitz JI. A high affinity interaction of plasminogen with fibrin is not essential for efficient activation by tissue-type plasminogen activator. J Biol Chem. February 10, 2012;287(7):4652-4661.
15. Gando S, Sawamura A, Hayakawa M. Trauma, shock, and disseminated intravascular coagulation: lessons from the classical literature. Ann Surg. 2011;254(1):10-19.
16. Kunadian V, Gibson CM. Recombinant tissue-type plasminogen activators: "time matters". Drugs Today (Barc). 2011;47(7):559-570.
17. Chen WH, Lin HS, Chen CI, etal. The medicolegal issue of tissue plasminogen activator in ischemic stroke: a review of judiciary decrees in Taiwan. Acta Neurol Taiwan. 2011;20(3):163-171.
18. Wu ZJ, Yang SF, Zheng SS, Shi D, Wu WW, Li DW. Construction and biological activities of human tPA eukaryotic expression plasmid. Hepatobiliary Pancreat Dis Int. 2004;3(4):511-515.
19. Ekhterae D, Stanley JC. Retroviral vector-mediated transfer and expression of human tissue plasminogen activator gene in human endothelial and vascular smooth muscle cells. J Vasc Surg. 1995;21(6):953-962.
20. Ji S, Ji J, Yang X, Wang X, Ling W, Zhang Y. Experimental study on construction of recombinant t-PA gene plasmid to prevent the thrombosis after mechanical valve replacement. South China J Cardiovas Dis. 2006;12(2):132-135.
21. Ji J, Zhang HW, Zhang ZJ, Ling WP. Transfection of tissue-type plasminogen activator gene to prevent vascular anastomotic restenosis after coronary bypass. China Journal of Modern Medicine. 2007;17(14):1683-1686.
22. Arnedo A, Irache JM, Merodio M, Espuelas Millán MS. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J Control Release. 2004;94(1):217-227.
23. Aynié I, Vauthier C, Chacun H, Fattal E, Couvreur P. Spongelike alginate nanoparticles as a new potential system for the delivery of antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1999;9(3):301-312.
24. Wang SB, Yuan F, Wu Y, etal. Nano-carriers for the target treatment of tumor. Journal of Clinical Rehabilitative Tissue Eng Res. 2009;13(29):5739-5742.
25. Wang ZX, Wang ZG. Treatment of ultrasound contrast agents for gene or drug delivery. Chin J Interv Imaging. 2006;3(4):304-308.
26. Casciaro S, Conversano F, Ragusa A, etal. Optimal enhancement configuration of silica nanoparticles for ultrasound imaging and automatic detection at conventional diagnostic frequencies. Invest Radiol. 2010;45(11):715-724.
27. Porter TR, Xie F. Therapeutic ultrasound for gene delivery. Echocardiography. 2001;18(4):349-353.
28. Zhao YZ, Lu CT. Recent advances in the applications of ultrasonic microbubbles as gene delivery systems. Yao Xue Xue Bao. 2007;42(2):127-131.
29. Lao Y, Xiu JC. Progress of ultrasound microbubble contrast agent with gene and drug targeting therapy. J Med Imaging. 2007;17(12):1359-1361.
30. Zhang YD, Guo Y, Liu WD. Albumin nanoparticles used as gene carrier. Chin J Exp Surg. 2004;21(12):1456-1458.
31. Du YF, Wan MX, Zhao WM. Study on the preparation of a new sugar albumin microbubble ultrasound contrast agent. Yao Xue Xue Bao. 2001;36(11):859-862.
32. Li Xin, He Sheng, GaoYunhua, etal. Study for preparing specific targeted ultrasound contrast agent. Chinese J Ultrasound Med. 2007;23(7):493-495.
33. Ling ZY, Wang Z, Ran HT, etal. Experiment study on ultrasound-mediated microbubble destruction deliver VEGF gene to ischemic myocardium of rats. Chinese Ultrasound Med. 2002;18(7):502-504.
34. Ji S, Jun J, Xiaohan Y, etal. Study on construction of nano tPA plasmid to prevent thrombosis after mechanical valve replacement in dogs. J Surg Res. 2011;168(1):e1-e5.
35. Arnedo A, Espuelas S, Irache JM. Albumin nanoparticles as carriers for a phosphodiester oligonucleotide. Int J Pharm. 2002;244(1-2):59-72.
36. Wang K, Ma GH. Preparation and characterization of albumin nanospheres as drug carrier. Chinese J Pro Eng. 2004;4(2):156-159.
37. Liu XB, Cai MY. Preparation and immunological characterization of mitoxantrone-loaded immuno-nanoparticles against human hepatoma. Chinese J Immuno. 2000;16(5):2622265-2622269.
38. Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng. 2007;9:415-447.
39. Chopra N, Doddamreddy P, Grewal H, Kumar PC. An elevated D-dimer value: a burden on our patients and hospitals. Int J Gen Med. 2012;5:87-92. Epub January 25, 2012.
40. Urano T, Suzuki Y. Parameters related to fibrinolysis and their meanings. Rinsho Byori. 2011;59(7):703-708.